Cancer-specific gene promoter methylation has been described in many types of cancers, and various semiquantified results have shown their usefulness. Here, we show a more sensitive and specific second-generation system for profiling the DNA methylation status. This method is based on bisulfite reaction of DNA and realtime PCR using two TaqMan MGB probes labeled with different fluorescence, followed by clustering analysis. Primers were designed with CpG-less sequences, and TaqMan MGB probes were designed to contain three or four CpG sites and to be shorter than conventional TaqMan probes. We have added new criteria for primer and probe design for further specificity. We confirmed the reliability of this system and applied it to analysis of lung cancers. Using 10 promoters, 90 primary lung cancers were clustered into six groups consisting of cases having similar smoking status and pathological findings. EGFR mutation and p16 promoter DNA methylation were exclusive, as previously reported; however, DNA methylation in other genes was unrelated to EGFR mutation. This system was also useful to distinguish double primary lung cancers from a single cancer with intrapulmonary metastasis. As above, our system has widespread availability in clinical use and biological research.
Introduction
Pathological classification has therapeutic significance in many types of hematological malignancies and solid tumors. The morphological characteristics in malignant cells are considered to represent their precursor cells, degree of differentiation and their biological character, and correlation with the clinical course is shown in many types of malignancies. However, in lung cancer, they are not enough to predict the prognosis or responsiveness to chemotherapy. Beyond morphological diagnosis, sophisticated methods of molecular biology, such as gene expression profiles (Alizadeh et al., 2000) and protein profiles (Chen et al., 2003) , have been applied in lymphomas and solid tumors. In lymphomas, such an approach has successfully established novel subcategories strongly related to clinical characteristics (Alizadeh et al., 2000) ; however, in solid tumors, such attempts face unsatisfactory results, thought to be a consequence of infiltration of inflammatory cells and proliferation of stromal cells associated within solid tumors. Methods that are more sensitive and specific to cancer were clearly needed.
DNA methylation, especially the methylation of cytosine of the CpG dinucleotide clustered in the promoter region of genes (CpG islands; recent characterization and definition is described in Takai and Jones, 2002) , is known to regulate gene expression in normal development such as X-chromosome inactivation (Panning and Jaenisch, 1998) and genomic imprinting (Feil and Khosla, 1999) , and is also well characterized in many cancers (reviewed in Jones and Baylin, 2002; Ushijima, 2005) . To map methylated cytosines, recent studies use bisulfite reaction (Frommer et al., 1992; Clark et al., 1994) and PCR. To date, aberrant promoter methylation has been analysed by methylation specific-PCR (MS-PCR) (Herman et al., 1996) , MethyLight (Eads et al., 2000) (real-time PCRbased method using primers and TaqMan probes to detect methylated CpGs after bisulfite reaction) and quantitative MS-PCR using the TaqMan probe and real-time PCR (Lehmann et al., 2001) . However, precise quantification of the methylation status of CpG islands was difficult, because the primers and probes for realtime PCR do not bind to DNA specifically enough after bisulfite reaction to distinguish methylated from unmethylated alleles. These methods had potential problems for precise quantification because of incomplete conversion by bisulfite reaction, differences in the amplification efficiency in following PCR between methylated and unmethylated DNA, and mis-annealing of primers and conventional TaqMan probes. In bisulfite reaction, unmethylated cytosines are converted to uracils whereas methylated cytosines are not; throughout PCR, uracils are replaced by thymine. Naturally, the potential amplified target sequence becomes less complicated and shows lower melting temperature, because they do not have any cytosine. Consequently, for unmethylated DNA, PCR primers, especially those that are long, lose their stringency compared with methylated DNA.
The minor groove binder (MGB) (Kutyavin et al., 2000) attached to the terminals of probes helps to bind probes to the target sequences at a much lower temperature than the estimated melting temperature and enables short probes to have a much better specificity at practical annealing temperatures. Application of TaqMan MGB probes to quantify the methylation status of promoter CpG islands (quantitative analysis of methylated alleles -QAMA) has been recently established (Zeschnigk et al., 2004) . We have applied QAMA with new criteria for primer and probe design to quantify the methylation status of multiple gene promoters with even higher precision, and used hierarchical clustering to categorize lung cancer specimens (Eisen et al., 1998) . We show that our method is useful for both cancer research and to make treatment decisions in the clinical setting.
Results

Quantitative methylation analysis
As described previously, primers were designed with CpG-less sequences and the length of the PCR products that contain a single CpG cluster for TaqMan MGB probes were minimized for equivalent amplification of methylated or unmethylated alleles ( Figure 1 and Table 1 ). TaqMan MGB probes were designed to contain three or four CpG sites that were specifically methylated in cancers. Probes that detect the methylated allele were labeled with VIC, and probes that detect the unmethylated allele were labeled with FAM.
In addition, we added two new criteria for primer and probe design for further specificity. We set the 3 0 end of primers as thymine converted from a non-CpG cytosine to avoid amplifying the alleles which were incompletely converted in bisulfite reaction. We set the 5 0 end of the probes on any nucleotide but thymine converted from non-CpG cytosine, to avoid the recognition of PCR products from incompletely converted DNA in bisulfite reaction. Theoretically, these additional criteria further reduce false-positive results from the original QAMA in some genes. Figure 1 An overview of primer/probe design and primers/probes used in this study. (a) Scheme of how to design primers and probes. Primers were designed with CpG-less sequences and the length of the PCR products that contain a minimum CpG cluster for TaqMan MGB probes were minimized for even amplification of methylated or unmethylated alleles. TaqMan MGB probes were designed, containing three of four CpG sites that were specifically methylated in cancers. (b) Map of promoter region of genes we analysed in this study. The start of open reading frame (ORF) is indicated by arrows, the primers are indicated by arrowheads, and the probe target site is indicated by boxes. For the best specificity to distinguish between methylated and unmethylated alleles, we designed primers and probes to meet the criteria described above. However, in some genes, PCR products were considerably long due to the gene structure.
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Four oligonucleotides are used in every reaction: two locus-specific PCR primers that contain at most one CpG site and amplify both methylated and unmethylated DNA after bisulfite reaction, and two TaqMan MGB probes that contain three or four CpG sites and labeled by fluorescence dye. The probe for methylated allele is labeled by VIC, and the probe for unmethylated allele is labeled by FAM. The Genbank accession number for each sequence is listed with the corresponding PCR amplicon location. The bisulfite-treated DNA strand (top or bottom) and probe-targeted strand (top or bottom) are also indicated. Other than these 10 genes, we tried to establish primers and probes of four genes: MTHFR, PTGS2, MGMT and RUNX3. For MTHFR, PTGS2 and MGMT, no methylation was detected from any of our samples. For RUNX3, we could not establish appropriate primers and probes; cross talk between the two probes was seen in spite of all our efforts at optimizing the condition.
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In this study, we selected 10 gene promoters (APC, p16, ESR1, CALCA, MYOD1, RASSF1A, RARB2, DAPK, TSLC1 and DBC1), some of which were reported for their usefulness for pathological classification of lung cancer cell lines (Virmani et al., 2002) and some whose aberrant methylation were associated with poor prognosis in operated patients (Brabender et al., 2001; Fukami et al., 2003; Wang et al., 2004; Izumi et al., 2005; Kim et al., 2005; Safar et al., 2005) .
For each gene, we optimized the PCR condition to yield a single PCR product and no methylation was confirmed in DNA from normal white blood cells or normal human bronchial epithelium (NHBE). They were used as the unmethylated control, and normal human white blood cell genomic DNA was treated with SssI methylase for the methylated control. We performed real-time PCR for each gene and obtained a standard curve from the data of fixed ratio of control genomic DNA and SssI methylase-treated DNA. In these experiments, TaqMan MGB probe had excellent specificity; cross talk between the probes against methylated or unmethylated targets was negligible. From these procedures, we obtained a reproducible standard curve.
Then we confirmed the sensitivity and specificity of this system. We detected methylation from the mixture of DNA containing 1% of methylated alleles (Figure 2a) . From the DNA containing only unmethylated alleles, we did not detected any methylation, even though no less than 60 cycles of PCR were performed (Figure 2b ).
Classification of lung cancers by methylation profile
We quantified the methylation status of DNA extracted from 90 resected samples of non-small cell lung cancer (NSCLC) patients. By duplicate quantification of methylation of lung cancer samples, we detected 0-98% methylation. Using hierarchical clustering analysis, the patients were divided into several clusters according to methylation profiles, and it showed a correlation with the histological subtype and smoking history (Figure 3) .
Relationship between EGFR mutation and promoter methylation status Additionally, we analysed the relationship between DNA methylation and EGFR mutation (Figure 3) . EGFR mutation and p16 promoter DNA methylation were exclusive except for one, a statistically significant differnce, as reported previously (Suzuki et al., 2006; Toyooka et al., 2006) . However, in other genes, DNA methylation was unrelated to EGFR mutation (statistically not significant).
Distinguishing between double primary lung cancers and a single cancer with intrapulmonary metastasis In these analyses, we included four cases having two cancers ( Figure 3 , indicated with arrows A-D). Three cases (cases A-C) had cancers of the same pathological type (Figure 4) . In cases A and B, two cancers had the same methylation profiles and belonged to the same cluster. Therefore, we could make the diagnosis as a single cancer with intrapulmonary metastasis, meaning stage IV. In case C, the methylation profile of the two cancers differed and belonged to different clusters. Therefore, we could make the diagnosis as double primary lung cancers, even though they showed the same pathological feature. In case D, both the methylation profiles and pathological type differed in the two cancers. The two cases with double primary lung cancer had two stage I cancers, which has a much better prognosis. We also analysed the methylation profile of primary lung cancer and lymph node metastasis, and they showed the same methylation profile (case E).
Discussion
We report a profiling system of multiple gene promoter methylation status, which is an application of QAMA, Figure 2 Stringency of detectability of methylation. As a representative curve, primer and probe pair of p16 is shown. We used normal white blood cells that were completely methylated by SssI methylase for the methylated control, and normal human bronchial epithelial cells for the unmethylated control. (a) Data from mixture of 1% of methylated control and 99% of unmethylated control. We could detect as little as 1% of methylated alleles. (b) Data from 100% of unmethylated control. We detected only 'FAM' signal. Our system showed no cross talk. We attempted the same detection by MethyLight, but we could not distinguish 1% methylation from no methylation (data not shown).
which enables more precise quantification of methylation, to multiple gene promoters.
To solve the problems of the conventional methods such as MS-PCR and MethyLight, we set additional criteria for primer and probe design when we applied the original QAMA in this study. In the original QAMA, primers were set in CpG-less sequences and were not used to distinguish methylation status. For discrimination between methylated and unmethylated alleles with highfidelity, we used QAMA-applied TaqMan MGB probes. Another advantage of QAMA was derived from quantifying both methylated and unmethylated alleles simultaneously in a single tube and determining the methylated ratio from fluorescence intensities. With conventional methods, excessive PCR cycles caused false-positive results, because methylation was detected by PCR primers and unconverted DNA in bisulfite reaction was also amplified by primers for methylated DNA. In QAMA, however, the number of PCR cycles did not influence the data, because the methylation was detected only by TaqMan MGB probe. In addition, we set the 3 0 end of primers as thymine converted from a non-CpG cytosine to avoid amplifying the alleles that were incompletely converted in bisulfite reaction. We set the 5 0 end of the probes on any nucleotide, but thymine converted from non-CpG cytosine, also to avoid the recognition of PCR products from incompletely converted DNA in bisulfite reaction. To minimize the influence of infiltration of inflammation and stromal cells, we applied cluster analysis of multiple genes to profile lung cancers.
Designing the primers and probes within CpG islands that meet stringent criteria (Takai and Jones, 2002) and within specifically methylated sequences described previously in cancers is quite difficult, and confirmation of methylation change in preliminary experiments is laborious. However, they are unavoidable for overcoming the problems associated with solid tumors. The brightness of red color represents the degree of methylation. In the smoking history column, 'H' stands for heavy smoker (more than 30 pack-years), 'L' stands for light smoker (30 pack-years or less), and 'N' stands for non-smoker. In the pathology column, 'AD' stands for adenocarcinoma, 'SQ' stands for squamous cell carcinoma, 'AD-SQ' stands for adenosquamous cell carcinoma, 'SCLC' stands for small cell lung cancer, 'GIANT' stands for giant cell carcinoma, 'LCNEC' stands for large cell neuroendocrine carcinoma, and 'PLEO' stands for pleomorphic carcinoma. In the EGFR mutation column, '19' stands for the point mutation of EGFR exon 19, and '21' stands for the deletion of EGFR exon 21. The cases who have double cancers are indicated as 'A', 'B', 'C' and 'D'. The cases 'E' and 'E-LN' are the same case and 'E-LN' is the lymph node metastasis from the lesion 'E'. The samples were generally separated according to pathological type and smoking habits. Group 'a' consists of only adenocarcinomas and most were non-smokers or light smokers and had EGFR mutation. These cases showed no p16 methylation and RARB2 methylation. Group 'b' contains several pathological type, various smoking habits and many EGFR mutation. They commonly showed RASSF1A methylation. EGFR mutation and p16 methylation were exclusive in both groups. Group 'c', in which all patients showed p16 methylation, consists of only smokers, contains many squamous cell carcinomas and no EGFR mutation. Group 'd', in which all patients have DBC1 methylation and no p16 methylation, contains many adenocarcinomas, but contains few EGFR mutation. Group 'e', in which there is no discriminative methylation, contains many adenocarcinomas and EGFR mutation. In group 'f', which is characterized by APC methylation, all patients are adenocarcinoma. Patients in group 'a' smoked significantly less (P ¼ 0.0003), and patient in group 'c' smoked significantly heavier (P ¼ 0.0323).
Taking these potential problems into account, our method is superior to other quantification methods of DNA methylation that quantify the methylation ratio of gene loci that are in the proximity but are different from those previously described, because methylation changes are specific and gene amplification are common in many solid tumors.
By applying modified QAMA to analyse multiple genes, we have quantified precisely the aberrant methylation of gene promoters and classified lung cancers by methylation status. Only bisulfite reactions, for which convenient kits are available, and real-time PCR were to be performed.
There have been several studies on quantitative methylation analysis for lung cancers. Virmani et al. (2002) reported the clustering of lung cancer cell line using DNA methylation markers. They successfully classified lung cancer cell lines by MethyLight. But it is difficult to apply it to lung cancer tissues, because they contained considerable amount of non-cancerous cells; ie proliferated stromal cells and cells related to inflammatory change. Tsou et al. (2005) successfully classified adenocarcinoma tissues, malignant mesothelioma tissues and non-tumor tissue by MethyLight and clustering. By progressing previous studies, we were able to classify lung cancer tissues precisely using QAMA and clustering.
Several previous studies have reported on the relationship between the methylation status of a gene and the prognosis. Gu et al. (2006) reported that patients with hypermethylated p16 was associated with significantly poorer survival, and hypermethylation of CDH1 or TIMP3 gene was associated with significantly better survival using quantitative MS-PCR. It is important to predict the prognosis for clinical use, and our method will allow us to do so. Therefore, we will have to follow up the patients and analyse the relationship between the prognosis and the groups classified by our quantitative methylation analysis with better sensitivity and specificity.
In lung cancer, both aberrant hypermethylation of gene promoters and EGFR mutation is known to occur often. It has been reported that hypermethylation of the p16 promoter detected by MS-PCR and mutation of EGFR occurred exclusively (Suzuki et al., 2006; Toyooka et al., 2006) , but the relationship between hypermethylation of other gene promoters and EGFR mutation was unknown. Our data showed that EGFR mutation and hypermethylation of p16 promoter were exclusive, as reported previously, and that nine other gene promoters were not related to EGFR mutation. Thus, there seems be some biological relationship between hypermethylation of p16 promoter and EGFR mutation.
EGFR mutation is seen in some cases of lung cancers, especially in adenocarcinomas. Our data showed the ratio of EGFR mutation differed among the groups classified according to methylation profiles (Figure 3 ). Groups 'a' and 'b' tended to contain many EGFR mutation cases, while group 'd' tended to contain few EGFR mutation cases, though it contains many adenocarcinomas (not statistically significant, P ¼ 0.178 by w 2 -test). These data suggest that adenocarcinomas should be classified into subgroups, and methylation profiling is useful for the classification.
In our study, the clonality of two cancers was diagnosed by the methylation profile of 10 genes. Patients who have two lung cancers consist of two entirely different groups, synchronous double primary cancers and cancers with intrapulmonary metastasis (Martini and Melamed, 1975) . The latter is stage IV, and shows a poor prognosis, while the former is as good as single early-stage lung cancer if each is found to be in early stage and curative operation is performed (Usuda et al., 1996) . However, it is often quite difficult to distinguish double primary cancers from intrapulmonary metastasis using conventional methods, especially Figure 4 Chest CT scan and hematoxylin-eosin stained section of two representative cases (cases A and C). (a) A 59-year-old man who smoked two packs a day for 32 years. The lesions were in the right upper lobe (A-1) and the left upper lobe (A-2). The lesions were resected by two-stage operations. The lesions were diagnosed as adenocarcinoma and they showed the same methylation profiles. Thus, we diagnosed them as a single cancer with intrapulmonary metastasis. (b) A 73-year-old man who smoked two packs a day for 45 years. The lesions were in the right lower lobe (C-1) and the right upper lobe (C-2). Both lesions were resected. Both lesions were diagnosed as moderately differentiated squamous cell carcinoma. In spite of the same pathological subtype, they had different methylation profiles. Thus we diagnosed them as double primary lung cancers.
A new methylation profiling system for cancers A Sano et al when the two cancers have the same pathological features. To distinguish them using a molecular biological approach, analysis of p53 gene mutations has been tried, but it has not become common (Mitsudomi et al., 1997) . Although we still need to prove that our method reflects the prognosis, we were successful in detecting the difference in clonality, an improvement on conventional pathologic methods. However, we were not able to perform statistical analysis, because patients who have multiple lesions are usually regarded as advanced and inoperable cases. Four patients who had two lesions were operated because radiological findings suggested double primary cancer. But they are generally rare, albeit important, cases.
As above, our system has availability for biological research and will be available for clinical use after validation by following up on the patients. Our system should become a second-generation system for quantitative methylation analysis for multiple gene promoters.
Materials and methods
Tumor DNA samples We analysed 90 tumor samples resected from 85 lung cancer patients after approval by the Institutional Ethics Review Committee and after obtaining informed consents of the patients. Sixty-eight were adenocarcinoma, 17 were squamous cell carcinoma, and five were other type of tumors. Sixty-one patients were smokers, and 24 were non-smokers. DNA was extracted by standard SDS/proteinase K method (Sambrook and Russel, 2001 ).
Bisulfite reaction
Bisulfite reaction was performed according to a protocol described previously (Takai et al., 2001) . In brief, genomic DNA (2 mg in 20 ml) was denatured by NaOH, sodium bisulfite and hydroquinone was added, and samples were incubated for 15 cycles of 951C for 15 s and 501C for 15 min. Converted DNA was purified using Wizard DNA Clean-Up System (Promega, Madison, WI, USA) and eluted into water, and NaOH was added for desulfonation. The converted DNA was precipitated by ethanol. The pellet was dissolved in water as template for QAMA.
QAMA
Real-time PCR was performed using a 96-well optical tray with caps at a final reaction volume of 25 ml. Samples contained 12.5 ml of real-time PCR Master Mix (Toyobo, Osaka, Japan), 1 ml of bisulfite-treated DNA solution, 0.8 mM of primers and 150 nM of TaqMan MGB probes (Applied Biosystems, Foster City, CA, USA), each for methylated and unmethylated alleles. DNA was amplified for 50 cycles at 951C for 15 s and 57-631C for 1 min (the detailed PCR condition in detail and sequences are noted in the Table 1 ). The amount of FAM and VIC fluorescence released from each tube was measured as a function of the PCR cycle number using the Mx3000P real-time PCR system (Stratagene, La Jolla, CA, USA).
Hierarchical clustering analysis
Hierarchical clustering analysis was performed by Cluster 3.0. (created by de Hoon et al., 2004; http://bonsai.ims.utokyo.ac.jp/Bmdehoon/software/cluster/). We did not adjust the raw data before clustering. We performed complete linkage clustering on our data. All of the genes were treated equally; we did not give weight to any genes. The data were visualized by Java TreeView (http://jtreeview.sourceforge.net/).
Data analysis
The number of cycles at which the fluorescence signal crosses a detection threshold is referred to as C T . The difference in the C T values within a sample (DC T ) was calculated. (The threshold is determined automatically by M Â 3000P real-time PCR system.) The relationship between the percentage of methylated DNA molecules (c) and C T is described as below:
DC T ¼ a þ b log ðc=1 À cÞ ða and b are constant numbersÞ:
For each gene, 'a' and 'b' were calculated by the least-squares method from the measured data of premixed controls with a methylation ratio of 10, 25, 50, 75 and 90%. From the formula, the percentage of methylated DNA molecules (c) of each sample was calculated.
